Generated by AI
Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing cardiovascular medicines for adults. Milestone Pharmaceuticals Inc.’s lead product, CARDAMYST (etripamil) nasal spray, is designed for the treatment of acute symptomatic episodes of paroxysmal supraventricular tachycardia, with additional development efforts in atrial fibrillation with rapid ventricular rate. The company centers its work on self-administered therapies that can be used outside the emergency department, addressing episodic heart rhythm conditions through a nasal spray delivery format. Based in Montreal, Canada, Milestone Pharmaceuticals Inc. serves the cardiovascular and biotechnology markets through its current product portfolio and ongoing clinical and commercial activities in the United States and Canada.
Website1111 Dr. Frederik-Philips Boulevard
Montreal, QC, H4M 2X6
Canada
The latest articles about MIST.
Milestone Pharmaceuticals is back in focus as updated fair value estimates move from US$5.71 per share to US$4.57, a cut of roughly 20% in the latest pricing work. Recent research points to optimism around Cardamyst’s long term potential along with concern about launch momentum and reimbursement, which helps explain why many price targets now cluster between US$3 and US$5. In the sections that follow, you will see how these shifting targets fit into the broader Milestone Pharmaceuticals story...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Jul 24's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Investors talking about MIST also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.